Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.72 |
| ▸ | RAF1 | P04049 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923555 | 0.91 | MAPK14 (0.84) | MAPK14MAPK11ERBB2MAPK13MAPT | |
| SCHEMBL669330 | 0.89 | MAPK14 (1.00) | MAPK14MAPK11ERBB2MAPK13MAPT | |
| SCHEMBL667670 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11ERBB2MAPK13MAPT | |
| SCHEMBL5732952 | 0.88 | MAPK14 (0.78) | MAPK14MAPK11ERBB2MAPK13MAPK12 | |
| SCHEMBL5571957 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11ERBB2MAPK13RAF1 | |
| SCHEMBL668120 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11ERBB2MAPK13RAF1 | |
| SCHEMBL939485 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11ERBB2MAPK13RAF1 | |
| SCHEMBL2959754 | 0.85 | MAPK14 (0.76) | MAPK14MAPK11ERBB2MAPK13MAPT | |
| SCHEMBL4594410 | 0.85 | MAPK14 (0.82) | MAPK14MAPK11ERBB2MAPK13MAPK12 | |
| SCHEMBL938855 | 0.84 | MAPK14 (0.75) | MAPK14MAPK11ERBB2MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160128974-A1 | ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-12 | — | — | US | claimed |
| US-9155723-B2 | Anti-CXCR4 as a sensitizer to cancer therapeutics | THE GENERAL HOSPITAL CORPORATION (US) | 2015-10-13 | — | — | US | claimed |
| US-20130216531-A1 | ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-22 | — | — | US | claimed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-20030049660-A1 | P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target | BAYLOR COLLEGE OF MEDICINE | 2003-03-13 | — | — | US | claimed |
| US-20250002844-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-02 | — | — | US | disclosed |
| US-12054741-B2 | Generation and maintenance of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-06 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| EP-1047418-B1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| CN-1544420-A | Inhibition of raf kinase using substituted heterocyclic ureas | — | 2004-11-10 | — | — | CN | disclosed |
| US-20030049660-A1 | P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target | BAYLOR COLLEGE OF MEDICINE | 2003-03-13 | — | — | US | disclosed |
| WO-2003000189-A2 | PREDICTION, DIAGNOSIS AND TREATMENT OF ENDOCRINE RESISTANT BREAST CANCER, USING P38 MAPK PATHWAY | BAYLOR COLLEGE OF MEDICINE (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | MAPK14 4493/4885MAPK11 3954/4885ERBB2 1593/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | MAPK14 4689/4885MAPK11 4323/4885ERBB2 2165/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | MAPK14 4493/4885MAPK11 3954/4885ERBB2 1593/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | MAPK14 4689/4885MAPK11 4323/4885ERBB2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.